Clinical trialNCT07011576RecruitingPhase 2Interventional

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

SponsorSCRI Development Innovations, LLCEnrollment60Colon CancerColorectal CancerColorectal Cancer (CRC)Rectal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: * Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting * Evaluate the safety of the combination of fruquintinib + FOLFIRI

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Meredith Pelster, MD
SCRI Oncology Partners
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rocky Mountain Cancer Center - Primary
Denver, Colorado, United States
Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Recruiting
Maryland Oncology Hematology
Columbia, Maryland, United States
Recruiting
Minnesota Oncology Hematology - Primary
Maple Grove, Minnesota, United States
Recruiting
Missouri Cancer Associates
Columbia, Missouri, United States
Recruiting
Oncology Associates of Oregon - Primary
Eugene, Oregon, United States
Recruiting
Northwest Cancer Specialists - Compass
Portland, Oregon, United States
Recruiting
Alliance Cancer Specialists
Wynnewood, Pennsylvania, United States
Recruiting
Scri Oncology Partners
Nashville, Tennessee, United States
Recruiting
Texas Oncology - Central/south Texas
Austin, Texas, United States
Recruiting
Texas Oncology - Gulf Coast
Beaumont, Texas, United States
Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas, United States
Recruiting
Virginia Oncology Associates
Norfolk, Virginia, United States
Recruiting
Blue Ridge Cancer Care (oncology & Hematology Associates of Southwest Va)
Salem, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FOLFIRIFruquintinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Sept 2025
Primary completion: 31 Jan 2027
Completion: 30 Jun 2027
Last update posted: 12 Jun 2026
Registered enrollment: 60
Registry id: NCT07011576

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.